Metabolic/Weight

HGH Fragment 176-191

Research Reagent · Laboratory Use Only

Quick Answer

How does HGH Fragment 176-191 differ from full human growth hormone in research models?

HGH Fragment 176-191 is a synthetic peptide derived from the C-terminal 16 amino acids of human growth hormone that retains the lipolytic activity of GH while lacking IGF-1 stimulation, hyperglycemia, and muscle growth effects. In preclinical research it demonstrates adipose-specific fat breakdown without the metabolic side effects of full-length GH.

PMID11713473↗DOI10.1006/jmbi.2001.5070↗⟳ Reconstitution Calculator
Scientific AbstractPMID 11713473 · 2001

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal 16 amino acids of the human growth hormone molecule. Preclinical research demonstrates that this fragment retains the lipolytic and anti-lipogenic activity of full-length growth hormone while lacking the hyperglycemic, IGF-1-stimulating, and growth-promoting effects. Animal studies show preferential breakdown of stored fat in adipose tissue with no measurable impact on muscle mass, insulin sensitivity, or organ growth. The fragment binds a distinct receptor site separate from the canonical GH receptor, accounting for the dissociation of metabolic and anabolic effects.

Source:10.1006/jmbi.2001.5070
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is HGH Fragment 176-191?

HGH Fragment 176-191 is a synthetic peptide derived from the C-terminal region of human growth hormone (residues 176-191) that isolates the lipolytic activity of growth hormone from its anabolic and glucoregulatory effects.

Mechanism of Action

The fragment binds receptors distinct from the canonical GHR (growth hormone receptor), activating adipocyte signaling that promotes triglyceride breakdown without engaging IGF-1 production pathways or insulin antagonism.

Observed Laboratory Results

  • Adipose-specific lipolysis without effects on muscle, organ growth, or blood glucose
  • No IGF-1 elevation distinguishing it from full GH and GH secretagogues
  • No hyperglycemic effect unlike full-length GH
  • Differential receptor binding versus full HGH explains the dissociated activity profile
Clinical Research ParametersHuman Study Registry

No registered clinical trials or indexed human study data currently available for HGH Fragment 176-191 via ClinicalTrials.gov or PubMed. This compound may be at preclinical or early research stages.

Search ClinicalTrials.gov ↗Search PubMed ↗
Research Compliance Notice

All data presented on this page is for laboratory research purposes only. HGH Fragment 176-191 is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 11713473) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Metabolic/Weight Research Compounds

Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the management of ob…
→
Tirzepatide
INTRODUCTION: Tirzepatide has been associated with significant reductions in body weight i…
→
Retatrutide
OBJECTIVES: Functional co- and tri-agonists at the receptors for GLP-1, GIP and glucagon e…
→
Liraglutide
PURPOSE: To evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 R…
→
View all Metabolic/Weight compounds →